



[Canada.ca](#) › [Departments and agencies](#) › [Health Canada](#) › [Drugs and health products](#)
› [Reports and Publications – Drugs and Health Products](#) › [Compliance and Enforcement](#)

Inspection tracker: Drug manufacturing establishments

As part of Health Canada's ongoing commitment to openness and transparency, the Department is publishing information regarding emerging issues identified through our drug inspection program.

This tracker provides a snapshot of the potential health and safety issues Health Canada is tracking with companies that fabricate, package/label, test, wholesale, distribute or import drugs for sale in Canada. The information in the chart will expand to eventually include details about affected Canadian companies and products.

How the inspection tracker works

- Health Canada responds to potential risks as soon as we hear about them whether from our own inspections, the companies themselves, adverse reaction reports or from our regulatory partners.
- The tracker highlights actions Health Canada is taking such as: requests for voluntary quarantine, stop sales, import restrictions, or product recalls. It also indicates those circumstances where no action has been warranted.
- Even if a company is listed on the tracker, it doesn't necessarily mean there is an immediate risk to the health of Canadians. It means Health

Canada is looking into a potential issue.

- Health Canada will continue to take action to manage risks identified to the health of Canadians using the most appropriate level of intervention, proportional to the risk to health.
- This tracker currently doesn't list specific drugs and health products affected but links to [Recalls and Safety Alerts](#) if a risk has been linked to specific products on the Canadian market.
- This tracker is updated regularly.
- Once an item is listed in the [closed section](#), it indicates that there is no further action being taken by Health Canada at this time and there will be no more updates regarding this item.
- Last update: **September 5, 2024**

Open items

Establishment	Status of issue	Source of information under review	Primary reason for action
<p>Aspen SA Sterile Operations 8b Gibaud Road, Port Elizabeth, Eastern Cape, South Africa</p> <p>New</p>	<ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner) 	Regulatory Partner(s)	General GMP observations

Establishment	Status of issue	Source of information under review	Primary reason for action
<p>Eugia Pharma Specialities Limited (Unit III) Plot No 4, 34 to 48, EPIP, TSIIC, IDA-Pashamylaram, Patancheru (Mandal), Sangareddy, Hyderabad, India</p>	<ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner • No further action required by Health Canada at this time 	Regulatory Partner(s)	General GMP observations
<p>Genzyme Corporation 8, 45, 51, 68, 74, 76 New York Avenue, Framingham, MA, 01701-9322, United States</p> <p>New</p>	<ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner • No further action required by Health Canada at this time 	Regulatory Partner(s)	General GMP observations

Establishment	Status of issue	Source of information under review	Primary reason for action
<p>Global Calcium Private Limited 125, 126 SIPCOT Industrial Complex, Hosur, Tamil Nadu, 635 126, India</p> <p>New</p>	<ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner • No further action required by Health Canada at this time 	Regulatory Partner(s)	General GMP observations
<p>Indoco Remedies Limited Plants II and III Goa L-32, 33, 34, Verna Industrial Area, India</p> <p>New</p>	<ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner 	Regulatory Partner(s)	General GMP observations

Establishment	Status of issue	Source of information under review	Primary reason for action
<p>Jagsonpal Pharmaceuticals B-1124, RIICO Industrial Area Phase III, Bhiwadi, Alwar, Rajasthan, India</p> <p>New</p>	<ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner 	Regulatory Partner(s)	General GMP observations
<p>Mylan Laboratories Limited (a Viatris company) Plot No. 11, 12 & 13, Indore SEZ Pharma Zone, Phase-II, Sector-III, Pithampur, Dhar, Madhya Pradesh, India</p> <p>New</p>	<ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner 	Regulatory partner(s)	General GMP observations





Establishment	Status of issue	Source of information under review	Primary reason for action
<p>Nectar Lifesciences Limited Village Bhatolikalan - Adjoining Jharmajri E.P.I.P., P.O. Barotiwala, Tehsil Baddi District Solan, Himachal Pradesh, 174 103, India</p> <p>New</p>	<ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner 	Regulatory Partner(s)	General GMP observations
<p>Tyche Industries 6 - 223 Sarpavaram (V), Kakinada, Andhra Pradesh India</p> <p>New</p>	<ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner 	Regulatory Partner(s)	General GMP observations

Establishment	Status of issue	Source of information under review	Primary reason for action
<p>Yung Shin Pharma 27 Kung Chiu Road, Tachia, 43769, Taiwan</p> <p>New</p>	<ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner 	Regulatory Partner(s)	General GMP observations





Filter items Showing 1 to 10 of 238 entries
 Show entries





Closed items





Establishment <input type="text" value="↑"/> <input type="text" value="↓"/>	Status of issue <input type="text" value="↑"/> <input type="text" value="↓"/>	Source of information under review <input type="text" value="↑"/> <input type="text" value="↓"/>	Primary reason for action <input type="text" value="↑"/> <input type="text" value="↓"/>
---	---	--	---





<p style="text-align: center;"></p> <p>Abraxis Bioscience LLC 620 N. 51st Avenue, Phoenix, AZ, 85043, United States</p>	<p style="text-align: center;"></p> <ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner) • No further action required by Health Canada at this time 	<p style="text-align: center;"></p> <p>Regulatory Partner(s)</p>	<p style="text-align: center;"></p> <p>General GMP observations</p>





<p style="text-align: center;"></p> <p>Accra Pac Inc. dba Voyant Beauty 1919 Superior Street, Elkhart, IN, 46516-4707, United States</p>	<p style="text-align: center;"></p> <ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e. corrective actions, information from regulatory partner) • No further action required by Health Canada at this time 	<p style="text-align: center;"></p> <p>Regulatory Partner(s)</p>	<p style="text-align: center;"></p> <p>General GMP observations</p>





<p style="text-align: center;"></p> <p>Accu Bio-Chem Laboratories 1755 Victory Boulevard, Glendale, CA, 91201, United States</p>	<p style="text-align: center;"></p> <ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner) • No further action required by Health Canada at this time 	<p style="text-align: center;"></p> <p>Regulatory Partner(s)</p>	<p style="text-align: center;"></p> <p>General GMP observations</p>





<p style="text-align: center;"></p> <p>Acharya Chemicals W41 &W42, MIDC Industrial estate - Morivali Village, 421501 AMBARNATH (W) (Dist Thane), 42150, India</p>	<p style="text-align: center;"></p> <ul style="list-style-type: none"> • Canadian importer contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner) • No further action required by Health Canada at this time 	<p style="text-align: center;"></p> <p>Regulatory Partner(s)</p>	<p style="text-align: center;"></p> <p>General GMP observations</p>





			
<p>Actavis Laboratories, FL. Inc., 4955 Orange Drive, Davie, Fort Lauderdale, Florida, USA, 33314</p>	<ul style="list-style-type: none"> • Canadian importer contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner) • Medically necessary products identified. • Issued terms and conditions to Canadian importer(s) • No further action required by Health Canada at this time 	<p>Regulatory Partner(s)</p>	<p>General GMP observations</p>





<p style="text-align: center;"></p> <p>Advanced Accelerator Applications USA, Inc. 57 East Willow Street, Millburn, NJ, 07041, United States</p>	<p style="text-align: center;"></p> <ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner) • No further action required by Health Canada at this time 	<p style="text-align: center;"></p> <ul style="list-style-type: none"> • Regulatory Partner(s) 	<p style="text-align: center;"></p> <p>General GMP observations</p>

<p style="text-align: center;"></p> <p>Advanced Cosmetic Research Laboratories Inc</p> <p>20550 Prairie St, Chatsworth, CA, 91311, United States</p>	<p style="text-align: center;"></p> <ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner) • No further action required by Health Canada at this time 	<p style="text-align: center;"></p> <p>Regulatory Partner(s)</p>	<p style="text-align: center;"></p> <p>General GMP observations</p>

<p style="text-align: center;"></p> <p>Agila Onco Therapies Ltd. Plot No. 284/B Bommasandra Jigani Link Road, Industrial Area, Bangalore, Karnataka, India</p>	<p style="text-align: center;"></p> <ul style="list-style-type: none"> • Non-compliant rating issued • No further action required by Health Canada at this time <p>Related recalls and alerts:</p> <ul style="list-style-type: none"> • <u>Methotrexate Injection USP 50 mg/2 mL - Voluntary Recall Due to the Potential Presence of Foreign Particulate Matter</u> 	<p style="text-align: center;"></p> <ul style="list-style-type: none"> • Regulatory Partner(s) • Canadian importer(s) 	<p style="text-align: center;"></p> <p>General GMP observations</p>

<p style="text-align: center;"></p> <p>AGILA SPECIALTIES PRIVATE LTD. Opp II M, Bilekahalli, Bannerghatta Road, Bangalore, Karnataka, India - 560 076</p>	<p style="text-align: center;"></p> <ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • No critical risks identified to date • No further action required by Health Canada at this time 	<p style="text-align: center;"></p> <p>Regulatory Partner(s)</p>	<p style="text-align: center;"></p> <p>General GMP observations</p>

			
<p>AGILA SPECIALTIES PRIVATE LTD., SPECIALTY FORMULATION FACILITY (SFF) 19A, Plot No. 284-B/1 Bommasandra Jigani Link Road, Anekal Taluk, Bangalore India - 560 105</p>	<ul style="list-style-type: none"> • Canadian importer(s) contacted by Health Canada for information • Continuing to review evidence submitted (i.e corrective actions, information from regulatory partner) • Medically necessary products identified • Requested voluntary quarantine of non-medically necessary products • Voluntary quarantine in place • Issued terms and conditions to Canadian importer(s) 	<p>Regulatory Partner(s)</p>	<p>General GMP observations</p>

			
	<ul style="list-style-type: none">• No further action required by Health Canada at this time		

- 1
- 2
- 3
- 4
- 5
- 24
- Next →

Date modified:

2025-03-04